Platelet transfusion therapy against chronic hepatitis and liver cirrhosis

Platelet transfusion therapy against chronic hepatitis and liver cirrhosis - Platelet transfusion therapy against chronic hepatitis and liver cirrhosis

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001164

Enrollment

Registered

2008-06-03

Start date

2008-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic hepatitis liver cirrhosis

Interventions

platelet transfusion 10U/week, 12 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)chronic hepatitis or Child-Pugh grade A or B 2)no malignancy 3)PS 0 or PS 1 4)no serious cardiovascular disease 5)agreement by documents 6)platelet counts were around 50 to 100 thousand/microlitter in previous year

Exclusion criteria

Exclusion criteria: 1)platelet count was less than 50 thousand/microlitter in the latest data 2)past history of shock on platelet transfusion 3)bone marrow transplantation(exept auto-transplantation) recipient or immunosuprrsive patients 4)IgA deficiency or other plasma protein deficiency 5)women with pregnancy, lactation or willing to get pregnant

Design outcomes

Primary

Measure	Time frame
fibrosis markers: type IV collagen, hyarulonic acid, PIIIP liver function: albumin, AST, ALT, bilirubin, prothrombin time	—

Secondary

Measure	Time frame
abdominal ultrasonography and CT platelet count anti-platelet antibody amount of hepatitis virus	—

Countries

Japan

Contacts

Public ContactNobuhiro Ohkohchi

Graduate School of Comprehensive Human Sciences, University of Tsukuba Department of Surgery

nokochi3@md.tsukuba.ac.jp029-853-3221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026